Novavax, Inc.

Novavax, Inc. Overview

Company Headquarters: Maryland, US

Founded: 1987

Workforce: ~2,500

Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa

Strategy

Novavax, Inc.'s main focus is to meet the unmet demand for emerging threats. It is focusing on building healthy relationships with academic and research institutes and pharmaceutical companies to develop cutting-edge biodefense solutions. Moreover, it is forming strategic alliances through funding and investment to support government agencies. Furthermore, it is committed to delivering novel products that leverage its innovative proprietary recombinant protein-based nanoparticle technology

Company Snapshot

$475.6M

Revenue

2,500

Employees

1987

Founded

Maryland, US

Headquarters

SWOT Analysis

Strengths

Strong pipeline of vaccine candidates
Skilled workforce
Company's strong financial position

Weaknesses

Challenges in manufacturing products

Opportunities

Increasing need of products to address the emerging threats
Company's partnerships with leading pharmaceutical companies
Expansion in new markets

Threats

Regulatory uncertainty
Change in public perception

Key Developments

Date	Approach	Development
February 2023	Partnership	Novavex, Inc. and U.S. Government extended their partnership and deliver up to 1.5 million doses of the Novavax vaccine. The contract has been supported through previously federal monies from Health and Human Services (US), the Administration for Strategic Preparedness and Response, and the Biomedical Advanced Research and Development Authority, administered by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense.
June 2020	Collaboration	Novavex, Inc. collaborated with Health and Human Services (US) and the Department of Defense (US) and signed an agreement worth USD 1,600 million in order to demonstrate commercial-scale manufacturing of the COVID-19 investigational vaccine.
June 2020	Investment	Novavex, Inc. received USD 60 million in funding from the US Department of Defense for the manufacturing of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.